Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Mismatch repair-deficient (MMRd) cancers exhibit high sensitivity to immunotherapy.
• Abundant neoantigens are thought to drive this sensitivity.
• The precise mechanisms linking MMR deficiency to immune response remain under investigation.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying the immunotherapy sensitivity of MMRd cancers.
• To investigate the role of MLH1 loss in immune activation pathways.
• To explore the connection between DNA repair defects and anti-tumor immunity.

Main Methods:

• Analysis of gene expression and protein signaling in MMRd cancer models.
• Assessment of cGAS-STING pathway activation.
• Evaluation of interferon secretion and T cell responses.
• Correlation of MLH1 status with immune cell infiltration and activity.

Main Results:

• MLH1 gene loss was shown to promote activation of the cGAS-STING signaling pathway.
• This activation led to increased interferon secretion.
• Enhanced T cell priming and activity were observed in the context of MLH1 deficiency.
• These findings suggest a direct link between MMR deficiency and immune system activation.

Conclusions:

• MLH1 deficiency in MMRd cancers actively promotes innate immune signaling via the cGAS-STING pathway.
• Interferon secretion and T cell priming are key consequences of this pathway activation.
• These immune responses may be critical for the observed high sensitivity of MMRd cancers to immunotherapy.
• Targeting this pathway could offer new therapeutic strategies for MMRd cancers.